NCT02150785 (AASIST) is a Phase 2 clinical trial of Streptokinase in Ischemic Stroke, sponsored by University of Alberta.

Who is sponsoring NCT02150785?

NCT02150785 is sponsored by University of Alberta.

What drugs are being tested in NCT02150785?

Interventions in NCT02150785: Streptokinase.

What condition does NCT02150785 study?

NCT02150785 studies Ischemic Stroke.

Is NCT02150785 still recruiting?

NCT02150785 is currently withdrawn. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT02150785: AASIST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Administering Streptokinase as a Thrombolytic Agent in the Management of Acute Stroke

Withdrawn Phase 2 Last updated 24 May 2022

What this trial tests

Phase 2 trial testing Streptokinase in Ischemic Stroke. Withdrawn.

Timeline

1 June 2014

Primary endpoint
1 June 2016

1 September 2016

Quick facts

Lead sponsor	University of Alberta
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 June 2014
Primary completion	1 June 2016
Estimated completion	1 September 2016

Drugs / interventions tested

Streptokinase — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

University of Alberta

Who can join

Adults 18 to 80, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess and measure the safety and efficacy of streptokinase (15 000 units/kg) as a successful and appropriate thrombolytic agent for ischemic stroke patients of low/middle income countries who can not afford the costly tissue plasminogen (tPA).
Time frame: 2 years
For safety, we will evaluate the presence of blood on CT scans done within 24 hours of the recruitment . Both asymptomatic and symptomatic hemorrhages will be recorded. For efficacy, the ninety day modified Rakin scale will be used.

Sponsor's own description

Currently, thrombolysis is offered to less than 1% of patients in low to middle income countries (LMICs) where access to health care is often based on the financial capabilities of the patient. There is therefore an urgent need for an effective but affordable alternative thrombolytic agent. Streptokinase (SK) ($35) is much more economically feasible as opposed to tissue plasminogen activator (tPA) ($2800). In this study, we propose a reevaluation of the use of streptokinase (SK) in the treatment of acute ischemic stroke. We want to emphasize that we will only consider this as a 'treatment option' if we are absolutely certain that IV tissue plasminogen activator (tPA) will not be offered to the patient due to its high cost. It is hypothesized that treatment with SK in appropriately selected patients will be associated with a hemorrhagic transformation rate similar to that of tPA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Streptokinase

Trials testing the same drug.

NCT03595085 — Catheter Directed Interventions in Pulmonary Embolism · NA · unknown
NCT03465085 — Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS · Phase 3 · completed

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02150785 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02150785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing